Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli.

@article{DiNicola2002HumanBM,
  title={Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli.},
  author={Massimo Di Nicola and Carmelo Carlo-Stella and Michele Magni and Marco Milanesi and Paolo Longoni and Paola Matteucci and Salvatore Grisanti and Alessandro Massimo Gianni},
  journal={Blood},
  year={2002},
  volume={99 10},
  pages={
          3838-43
        }
}
CD2(+) T lymphocytes obtained from either the donor of bone marrow stromal cells (BMSCs) or a third party were cultured in mixed lymphocyte reactions (MLRs) with either allogeneic dendritic cells (DCs) or peripheral blood lymphocytes (PBLs). When autologous or allogeneic BMSCs were added back to T cells stimulated by DCs or PBLs, a significant and dose-dependent reduction of T-cell proliferation, ranging from 60% +/- 5% to 98% +/- 1%, was evident. Similarly, addition of BMSCs to T cells… 

Figures and Tables from this paper

Generation of CD4+ or CD8+ regulatory T cells upon mesenchymal stem cell-lymphocyte interaction.

Findings indicate that powerful regulatory CD4+ or CD8+ lymphocytes are generated in co-cultures of PBMC with MSC, which strongly suggests that these regulatory cells may amplify the reported MSC-mediated immunosuppressive effect.

Human bone marrow mesenchymal stem cells and chondrocytes promote and/or suppress the in vitro proliferation of lymphocytes stimulated by interleukins 2, 7 and 15

There is a dichotomous effect of MSCs/ACs on lymphocytes proliferating in response to the homeostatic IL2, IL7 and IL15 cytokines likely to be encountered in homeostatics and autoimmune inflammatory conditions.

Mesenchymal stem cells do not suppress lymphoblastic leukemic cell line proliferation.

Using Jurkat cells as a model of leukemia T cells, results indicated an uncertainty about the suppressive effect of MSCs and their inhibitory metabolites on tumor or leukemia cell proliferation.

Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway

Bone marrow mesenchymal progenitor cells are used for regenerating tissues of mesodermal origin, as well as tissues of different embryological derivation and the possibility of their therapeutic application in transplantation and autoimmune diseases is asserted.

T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression.

It is concluded that MSCs can initiate activation of alloreactive T cells, but do not elicit T cell proliferative responses due to active suppressive mechanisms.

Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells

The findings indicate that MSCs escape recognition by CTLs and alloreactive NK cells, and inhibit the formation of cytotoxic T cells by secreting a soluble factor, but that they do not interfere with C TLs and NK cell lysis.

Mesenchymal stromal cells inhibit proliferation of virus-specific CD8+ T cells

It is confirmed that MSCs strongly inhibited proliferation of CD8+ T cells in a mixed lymphocyte reaction, and also suppressed proliferation of T cells specifically recognizing cytomegalovirus (CMV) and influenza virus.
...

References

SHOWING 1-10 OF 42 REFERENCES

Reduced expression of vascular cell adhesion molecule-1 on bone marrow stromal cells isolated from marrow transplant recipients correlates with a reduced capacity to support human B lymphopoiesis in vitro.

The collective results may provide new mechanistic insight into why B-cell recovery is delayed post-BMT and underscore the importance of VCAM-1/CD106 in regulating B lymphopoiesis.

Limited engraftment capacity of bone marrow-derived mesenchymal cells following T-cell-depleted hematopoietic stem cell transplantation.

M marrow stromal progenitors reinfused in patients receiving a sex-mismatched, T-cell-depleted allograft have a limited capacity of reconstituting marrow mesenchymal cells.

Expression of CD10 by human T cells that undergo apoptosis both in vitro and in vivo.

Observations indicate that CD10 may represent a reliable marker for identifying and isolating apoptosing T cells in vitro and ex vivo and possibly suggest novel functions for surface CD10 in the apoptotic process of lymphoid cells.

Recovery of immune reactivity after T-cell-depleted bone marrow transplantation depends on thymic activity.

It is concluded that during the first year after transplantation, the absence of an immune response is due mainly to the loss of an adequate T-cell repertoire.

Host origin of marrow stromal cells following allogeneic bone marrow transplantation

Using in situ hybridization to discriminate donor cells from host in blood and bone marrow samples obtained from patients with functioning sex-mismatched but HLA-identical allografts, marrow-derived stromal cells that proliferate in long-term cultures were found to be of host genotype, whereas the macrophage component of the adherent layer in these cultures originated from the donor.

Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use.

A phase I trial to determine the feasibility of collection, ex vivo culture-expansion and intravneous infusion of human bone marrow-derived progenitor stromal cells (MPCs) obtained from cancer patients found they can be collected, expanded in vitro and infused intravenously without toxicity.

Cells Capable of Bone Production Engraft from Whole Bone Marrow Transplants in Nonablated Mice

It is demonstrated for the first time that a whole bone marrow transplant contains cells that engraft and become competent osteoblasts capable of producing bone matrix.